<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047211</url>
  </required_header>
  <id_info>
    <org_study_id>21-0127</org_study_id>
    <nct_id>NCT05047211</nct_id>
  </id_info>
  <brief_title>Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia</brief_title>
  <acronym>IVIRONMAN</acronym>
  <official_title>A Feasibility Trial of Intravenous Iron vs. Oral Iron Supplementation for the Treatment of Postpartum Anemia (IVIRONMAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be a comparative pragmatic open label feasibility randomized controlled trial&#xD;
      of oral daily versus IV iron in anemic postpartum patients.&#xD;
&#xD;
      Two randomly assigned groups will be compared during the postpartum period:&#xD;
&#xD;
        1. Oral Iron group: Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6&#xD;
           weeks TID.&#xD;
&#xD;
           IV placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home&#xD;
           over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride.&#xD;
&#xD;
        2. IV Iron group: Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9%&#xD;
           500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron&#xD;
           dextran infusion in 100mL 0.9% sodium chloride.&#xD;
&#xD;
      2.1 Oral placebo will be given by mouth for a total of 6 weeks TID.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded placebo controlled clinical trial. We will be using intravenous and oral placebos for each interventions</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>6 weeks after delivery</time_frame>
    <description>hemoglobin in grams per deciliters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>arthralgia</measure>
    <time_frame>up to 6 weeks after delivery</time_frame>
    <description>Joint pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Backache</measure>
    <time_frame>up to 6 weeks after delivery</time_frame>
    <description>Back pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>up to 6 weeks after delivery</time_frame>
    <description>Temperature &gt; 100.4 Fahrenheit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea or vomiting</measure>
    <time_frame>up to 6 weeks after delivery</time_frame>
    <description>feeling sick to vomit or vomit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myalgia</measure>
    <time_frame>up to 6 weeks after delivery</time_frame>
    <description>Generalized muscle pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anemia, Iron Deficiency</condition>
  <condition>Delivery Complication</condition>
  <arm_group>
    <arm_group_label>Oral Iron group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6 weeks three times daily.&#xD;
Intravenous placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Iron group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9% 500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron dextran infusion in 100mL 0.9% sodium chloride.&#xD;
Oral placebo will be given by mouth for a total of 6 weeks TID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous sulfate</intervention_name>
    <description>one tablet 325 milligrams three times a day</description>
    <arm_group_label>Oral Iron group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron dextran</intervention_name>
    <description>1000 mg intravenous infusion</description>
    <arm_group_label>IV Iron group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Delivery at our institution&#xD;
&#xD;
          -  Hemoglobin below 9 g/dl in postpartum day 1&#xD;
&#xD;
          -  Singleton gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of malabsorptive disorder or history of gastric bypass procedure&#xD;
&#xD;
          -  Known diagnosis of anemia other than iron deficiency (thalassemia, macrocytic anemia,&#xD;
             sickle cell, etc.)&#xD;
&#xD;
          -  Significant cardiovascular disease, including but not limited to myocardial infarction&#xD;
             or unstable angina within 6 months prior to study inclusion or current history of NYHA&#xD;
             Class III or IV congestive heart failure&#xD;
&#xD;
          -  Patient has received blood transfusion or there is a plan to transfuse&#xD;
&#xD;
          -  Lactose intolerance&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participant eligibility is based on self-representation of gender identity.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ashley Salazar</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Saad, MD</last_name>
      <phone>409-772-0982</phone>
      <email>afsaad@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Salazar</last_name>
      <phone>140927720312</phone>
      <email>assalaza@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Saad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Saade, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpartum, iron deficiency anemia, intravenous iron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextrans</mesh_term>
    <mesh_term>Iron-Dextran Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

